UY35023A - Derivados c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso - Google Patents
Derivados c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de usoInfo
- Publication number
- UY35023A UY35023A UY0001035023A UY35023A UY35023A UY 35023 A UY35023 A UY 35023A UY 0001035023 A UY0001035023 A UY 0001035023A UY 35023 A UY35023 A UY 35023A UY 35023 A UY35023 A UY 35023A
- Authority
- UY
- Uruguay
- Prior art keywords
- methods
- derivatives
- alquendiilo
- alcandiilo
- oleanolic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Epidemiology (AREA)
Abstract
Nuevos derivados C17-alcandiilo y alquendiilo, que incluyen los derivados de la siguiente fórmula: (I), en donde las variables son como se definen en la presente. También se proveen composiciones farmacéuticas, conjuntos de elementos y artículos de manufactura que comprenden dichos compuestos. Se proveen asimismo métodos e intermediarios que son de utilidad para elaborar los compuestos, y métodos para utilizar los compuestos, por ejemplo como moduladores antioxidantes de inflamación, y composiciones con los mismos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261699122P | 2012-09-10 | 2012-09-10 | |
US201361780540P | 2013-03-13 | 2013-03-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY35023A true UY35023A (es) | 2014-03-31 |
Family
ID=49253402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001035023A UY35023A (es) | 2012-09-10 | 2013-09-10 | Derivados c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso |
Country Status (38)
Country | Link |
---|---|
US (2) | US9593074B2 (es) |
EP (1) | EP2892912B1 (es) |
JP (1) | JP6243428B2 (es) |
KR (1) | KR102237359B1 (es) |
CN (1) | CN104955833B (es) |
AR (1) | AR092506A1 (es) |
AU (1) | AU2013312106B2 (es) |
BR (1) | BR112015005168A2 (es) |
CA (1) | CA2882418C (es) |
CL (1) | CL2015000543A1 (es) |
CR (1) | CR20150117A (es) |
CY (1) | CY1121776T1 (es) |
DK (1) | DK2892912T3 (es) |
DO (1) | DOP2015000054A (es) |
EA (1) | EA029174B1 (es) |
ES (1) | ES2731758T3 (es) |
HK (1) | HK1212355A1 (es) |
HR (1) | HRP20191165T1 (es) |
HU (1) | HUE044126T2 (es) |
IL (1) | IL237639B (es) |
IN (1) | IN2015DN01442A (es) |
LT (1) | LT2892912T (es) |
ME (1) | ME03522B (es) |
MX (1) | MX366913B (es) |
MY (1) | MY180903A (es) |
NZ (1) | NZ630967A (es) |
PE (1) | PE20150627A1 (es) |
PH (1) | PH12015500491B1 (es) |
PL (1) | PL2892912T3 (es) |
PT (1) | PT2892912T (es) |
RS (1) | RS59194B1 (es) |
SG (1) | SG11201501792RA (es) |
SI (1) | SI2892912T1 (es) |
TW (1) | TWI630212B (es) |
UA (1) | UA115672C2 (es) |
UY (1) | UY35023A (es) |
WO (1) | WO2014040060A1 (es) |
ZA (1) | ZA201501206B (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4923146B2 (ja) | 2008-01-11 | 2012-04-25 | リアタ ファーマシューティカルズ インコーポレイテッド | 合成トリテルペノイドおよび疾患の治療における使用方法 |
ES2703274T3 (es) | 2008-04-18 | 2019-03-07 | Reata Pharmaceuticals Inc | Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17 |
JP5564490B2 (ja) | 2008-04-18 | 2014-07-30 | リアタ ファーマシューティカルズ インコーポレイテッド | 抗炎症性ファルマコアを含む化合物および使用法 |
LT2651902T (lt) | 2010-12-17 | 2018-01-10 | Reata Pharmaceuticals, Inc. | Tricikliniai pirazolil- ir pirimidinilenonai, kaip antioksidantų uždegimo moduliatoriai |
MX349739B (es) * | 2012-03-20 | 2017-08-10 | Firmenich & Cie | Compuestos para una liberacion controlada de moleculas perfumantes activas. |
TWI623548B (zh) | 2012-04-27 | 2018-05-11 | 瑞塔醫藥有限責任公司 | 齊墩果酸(bardoxolone methyl)之2,2-二氟基丙醯胺衍生物、多晶型及其使用方法 |
US9556222B2 (en) | 2012-06-15 | 2017-01-31 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
MY180903A (en) | 2012-09-10 | 2020-12-11 | Reata Pharmaceuticals Inc | C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof |
US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
AR096046A1 (es) | 2013-04-24 | 2015-12-02 | Abbvie Inc | Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso |
CN107428698B (zh) | 2015-02-12 | 2021-10-26 | 里亚塔医药公司 | 作为抗氧化炎症调节剂的咪唑基三环烯酮 |
CN108290922B (zh) | 2015-09-23 | 2021-12-07 | 里亚塔医药公司 | 用于抑制il-17和其它用途的c4-改性的齐墩果酸衍生物 |
US10953020B2 (en) | 2016-11-08 | 2021-03-23 | Reata Pharmaceuticals, Inc. | Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof |
TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物 |
CA3075729A1 (en) | 2017-09-14 | 2019-03-21 | Phoenix Biotechnology, Inc. | Use of oleandrin to treatn viral infection |
CN111417384A (zh) | 2017-09-14 | 2020-07-14 | 菲尼克斯生物技术公司 | 用于治疗神经系统病况的方法和改进的神经保护性组合物 |
US9896476B1 (en) | 2017-09-21 | 2018-02-20 | King Saud University | Glycyrrhetic acid derivatives |
CA3103726A1 (en) | 2018-06-15 | 2019-12-19 | Reata Pharmaceuticals, Inc. | Pyrazole and imidazole compounds for inhibition of il-17 and rorgamma |
CN108640965B (zh) * | 2018-06-23 | 2021-11-05 | 沈阳药科大学 | 2-取代-18β-甘草次酸衍生物及其应用 |
WO2021201903A1 (en) | 2020-03-31 | 2021-10-07 | Phoenix Biotechnology, Inc. | Method and compositions for treating coronavirus infection |
EP4295854A3 (en) | 2020-03-31 | 2024-04-03 | Phoenix Biotechnology, Inc. | Method and compositions for treating coronavirus infection |
WO2022126129A1 (en) | 2020-12-11 | 2022-06-16 | Reata Pharmaceuticals, Inc. | Synthetic triterpenoids for use in therapy |
AU2022208727A1 (en) * | 2021-01-18 | 2023-08-03 | Reata Pharmaceuticals, Inc. | Synthetic ursolic acid derivatives and methods of use thereof |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4395423A (en) | 1978-10-10 | 1983-07-26 | Sterling Drug Inc. | Polycyclic cyanoketones |
NZ191586A (en) | 1978-10-10 | 1981-10-19 | Sterling Drug Inc | Cyanoketones derived from glycyrrhetinic acid and pharmaceutical compositions |
US5064823A (en) | 1988-08-24 | 1991-11-12 | Research Triangle Institute | Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers |
US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
US6369101B1 (en) | 1999-02-26 | 2002-04-09 | Regents Of The University Of Minnesota | Therapeutic method to treat herpes virus infection |
BR0011522A (pt) | 1999-05-14 | 2002-06-04 | Nereus Pharmaceuticals Inc | Composto e método de sintetização para a fabricação do composto |
US6649654B1 (en) | 1999-11-23 | 2003-11-18 | The Regents Of The University Of California | Methods for identifying and using IKK inhibitors |
JP2001240573A (ja) * | 2000-03-01 | 2001-09-04 | Meiji Seika Kaisha Ltd | トリテルペン誘導体及び肝疾患治療剤 |
WO2002003996A1 (en) | 2000-07-12 | 2002-01-17 | RAJKUMAR, Sujatha | Use of dammarane-type tritepenoid saporins |
AU2001294959A1 (en) | 2000-09-29 | 2002-04-08 | Robert M. Carlson | Triterpenes having antibacterial activity |
US6951847B2 (en) | 2000-09-29 | 2005-10-04 | Regents Of The University Of Minnesota | Methods of treating fungal infections using lupeol |
US6642217B2 (en) | 2000-09-29 | 2003-11-04 | Naturtek, Llc | Triterpenes having human antifungal and antiyeast activity |
US6878751B1 (en) | 2000-10-19 | 2005-04-12 | Imperial College Of Science Technology And Medicine | Administration of resveratrol to treat inflammatory respiratory disorders |
US7435755B2 (en) | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
CA2430454A1 (en) | 2000-11-28 | 2002-06-20 | Board Of Regents, The University Of Texas System | Cddo-compounds and combination therapies thereof |
WO2002092768A2 (en) | 2001-05-14 | 2002-11-21 | University Of Maryland, Baltimore | Novel alanine transaminase enzyme and methods of use |
US7176237B2 (en) | 2002-01-15 | 2007-02-13 | The Trustees Of Dartmouth College | Tricyclic-bis-enone derivatives and methods of use thereof |
DE60325329D1 (de) | 2002-01-18 | 2009-01-29 | Univ Minnesota | Quaternäre terpensalze als biologisch aktive tenside |
EP1507541A4 (en) | 2002-05-13 | 2009-06-03 | Dartmouth College | HEMMER AND APPLICATION METHOD THEREFOR |
US20050014730A1 (en) | 2003-04-02 | 2005-01-20 | Carlson Robert M. | Anti-fungal formulation of triterpene and essential oil |
AU2005282437B2 (en) | 2004-09-07 | 2013-01-10 | Pacific Arrow Limited | Anti-tumor compounds with angeloyl groups |
WO2005042002A2 (en) | 2003-10-30 | 2005-05-12 | Entelos, Inc. | Treatment of rhematoid arthritis with flip antagonists |
WO2005046732A2 (en) | 2003-11-04 | 2005-05-26 | THE UNITED SATES OF AMERICA as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES, NIH | Methods and compositions for the inhibition of hiv-1 replication |
US20060258752A1 (en) | 2004-02-12 | 2006-11-16 | Vander Jagt David L | Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors |
JP2005314381A (ja) | 2004-03-30 | 2005-11-10 | Anges Mg Inc | 増殖性腎疾患の予防・治療・改善剤 |
EP1959969A2 (en) | 2005-07-01 | 2008-08-27 | The Johns Hopkins University | Compositions and methods for the treatment or prevention of disorders relating to oxidative stress |
EP1996205A2 (en) | 2006-03-23 | 2008-12-03 | Advanced Life Sciences Inc. | Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin |
US20070249561A1 (en) | 2006-04-25 | 2007-10-25 | Taylor Bradley K | Pharmacological method for treatment of neuropathic pain |
WO2008000068A1 (en) | 2006-06-27 | 2008-01-03 | Wellington Laboratories Inc. | Method for preparing 2-iodo triterpenoid compounds |
CN101117348B (zh) | 2006-08-01 | 2010-12-29 | 浙江海正药业股份有限公司 | A环和c环多氧化取代的五环三萜及其制备方法和用途 |
JP2008110962A (ja) | 2006-08-02 | 2008-05-15 | Santen Pharmaceut Co Ltd | Nrf2活性化物質を有効成分として含む角結膜障害の予防または治療剤 |
WO2008016095A1 (fr) | 2006-08-02 | 2008-02-07 | Santen Pharmaceutical Co., Ltd. | REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE |
WO2008064133A1 (en) | 2006-11-17 | 2008-05-29 | Trustees Of Dartmouth College | Synthesis and biological activities of new tricyclic-bis-enones (tbes) |
US8299046B2 (en) | 2006-11-17 | 2012-10-30 | Trustees Of Dartmouth College | Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth |
LT2653873T (lt) | 2007-02-08 | 2022-10-10 | Biogen Ma Inc. | Kompozicijos ir naudojimas, skirti išsėtinei sklerozei gydyti |
WO2008111497A1 (ja) | 2007-03-08 | 2008-09-18 | Santen Pharmaceutical Co., Ltd. | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
US20080254055A1 (en) * | 2007-04-11 | 2008-10-16 | John Erich Oblong | Compositions for Regulation of Hair Growth |
WO2008136838A1 (en) | 2007-05-04 | 2008-11-13 | Trustees Of Dartmouth College | Novel amide derivatives of cddo and methods of use thereof |
US20090048205A1 (en) | 2007-08-15 | 2009-02-19 | Colin Meyer | Combination therapy with synthetic triterpenoids and gemcitabine |
US8088824B2 (en) | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
WO2009058849A1 (en) | 2007-10-29 | 2009-05-07 | University Of Rochester | Use of electrophilic compounds for inducing platelet production or maintaining platelet function |
JP4923146B2 (ja) | 2008-01-11 | 2012-04-25 | リアタ ファーマシューティカルズ インコーポレイテッド | 合成トリテルペノイドおよび疾患の治療における使用方法 |
CN102164941B (zh) * | 2008-04-18 | 2015-05-27 | 里亚塔医药公司 | 抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物 |
JP5564490B2 (ja) | 2008-04-18 | 2014-07-30 | リアタ ファーマシューティカルズ インコーポレイテッド | 抗炎症性ファルマコアを含む化合物および使用法 |
ES2703274T3 (es) | 2008-04-18 | 2019-03-07 | Reata Pharmaceuticals Inc | Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17 |
WO2009146216A2 (en) | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals. Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
EP2271658B1 (en) * | 2008-04-18 | 2016-11-09 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives |
US8314137B2 (en) | 2008-07-22 | 2012-11-20 | Trustess Of Dartmouth College | Monocyclic cyanoenones and methods of use thereof |
WO2010053817A1 (en) | 2008-11-04 | 2010-05-14 | Trustees Of Dartmouth College | Betulinic acid derivatives and methods of use thereof |
SI2395979T1 (sl) | 2009-02-13 | 2017-12-29 | Reata Pharmaceuticals, Inc. | Peroralni farmacevtski sestavki, ki vsebujejo amorfni CDDO-Me, z zapoznelim sproščanjem |
WO2011130302A2 (en) | 2010-04-12 | 2011-10-20 | Reata Pharmaceuticals, Inc. | Method of treating obesity using antioxidant inflammation modulators |
WO2011140078A1 (en) | 2010-05-04 | 2011-11-10 | Concert Pharmaceuticals, Inc. | Synthetic triterpenoid derivatives |
CN102079772A (zh) | 2010-12-09 | 2011-06-01 | 中国药科大学 | 一类五环三萜-13,28-内酯化合物、其制备方法和用途 |
CN102070697A (zh) | 2010-12-09 | 2011-05-25 | 中国药科大学 | 一种齐墩果酸衍生物、其制备方法及用途 |
LT2651902T (lt) | 2010-12-17 | 2018-01-10 | Reata Pharmaceuticals, Inc. | Tricikliniai pirazolil- ir pirimidinilenonai, kaip antioksidantų uždegimo moduliatoriai |
CA2826113C (en) | 2011-01-31 | 2018-09-04 | Bristol-Myers Squibb Company | C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity |
CN102093462B (zh) | 2011-02-28 | 2012-11-21 | 贵州省中国科学院天然产物化学重点实验室 | 1α,2α-二羟基齐墩果酸的制备方法和应用 |
ME03469B (me) * | 2011-03-11 | 2020-01-20 | Reata Pharmaceuticals Inc | DERIVATI C4-MONOMETIL TRITERPENOIDA l POSTUPCI ZA NJIHOVU UPOTREBU |
WO2012154554A1 (en) | 2011-05-06 | 2012-11-15 | Catabasis Pharmaceuticals, Inc. | Fatty acid triterpene derivatives and their uses |
CN102250189B (zh) | 2011-05-20 | 2012-08-29 | 中国药科大学 | 一种具有1,12-二烯-3-酮骨架的甘草次酸衍生物、其制备方法及医药用途 |
TWI623548B (zh) | 2012-04-27 | 2018-05-11 | 瑞塔醫藥有限責任公司 | 齊墩果酸(bardoxolone methyl)之2,2-二氟基丙醯胺衍生物、多晶型及其使用方法 |
US8981144B2 (en) | 2012-05-08 | 2015-03-17 | Trustees Of Dartmouth College | Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof |
WO2013169740A2 (en) | 2012-05-08 | 2013-11-14 | Trustees Of Dartmouth College | Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression |
US8921419B2 (en) | 2012-05-08 | 2014-12-30 | Trustees Of Dartmouth College | Triterpenoids and compositions containing the same |
JP6272312B2 (ja) | 2012-05-29 | 2018-01-31 | パリオン・サイエンシィズ・インコーポレーテッド | ドライアイおよび他の粘膜疾患の治療のためのナトリウムチャネル遮断活性を有するデンドリマー様アミノアミド |
US9556222B2 (en) | 2012-06-15 | 2017-01-31 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
MY180903A (en) | 2012-09-10 | 2020-12-11 | Reata Pharmaceuticals Inc | C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof |
MX2015003021A (es) | 2012-09-10 | 2015-11-09 | Abbvie Inc | Derivados de acido glicirretinico y metodos de uso de los mismos. |
DK2892911T3 (en) | 2012-09-10 | 2017-10-23 | Reata Pharmaceuticals Inc | C17 heteroaryl derivatives of oleanolic acid and methods of use thereof |
US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
US9278912B2 (en) | 2012-09-10 | 2016-03-08 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
CN104603125A (zh) | 2012-09-10 | 2015-05-06 | 弗·哈夫曼-拉罗切有限公司 | 用于治疗和预防乙型肝炎病毒感染的6-氨基酸杂芳基二氢嘧啶 |
EP2739639A4 (en) | 2012-09-28 | 2014-11-05 | Applied Pharmaceutical Science Inc | POLYMORPHS OF CDDO ETHYL ESTER AND USES THEREOF |
CN102887936A (zh) | 2012-10-24 | 2013-01-23 | 苏州晶云药物科技有限公司 | 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型 |
CN103788166A (zh) | 2012-10-30 | 2014-05-14 | 中国药科大学 | △13(18)-cddo衍生物、其制备方法与在制药中的用途 |
AR096046A1 (es) | 2013-04-24 | 2015-12-02 | Abbvie Inc | Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso |
TWI716341B (zh) | 2013-08-23 | 2021-01-21 | 美商瑞塔醫藥有限責任公司 | 使用齊墩果酸(bardoxolone methyl)或其類似物治療和預防內皮功能障礙之方法 |
CN108290922B (zh) | 2015-09-23 | 2021-12-07 | 里亚塔医药公司 | 用于抑制il-17和其它用途的c4-改性的齐墩果酸衍生物 |
-
2013
- 2013-09-10 MY MYPI2015000568A patent/MY180903A/en unknown
- 2013-09-10 EA EA201590540A patent/EA029174B1/ru not_active IP Right Cessation
- 2013-09-10 US US14/022,986 patent/US9593074B2/en active Active
- 2013-09-10 IN IN1442DEN2015 patent/IN2015DN01442A/en unknown
- 2013-09-10 KR KR1020157009157A patent/KR102237359B1/ko active IP Right Grant
- 2013-09-10 LT LTEP13767176.4T patent/LT2892912T/lt unknown
- 2013-09-10 AR ARP130103221A patent/AR092506A1/es active IP Right Grant
- 2013-09-10 CA CA2882418A patent/CA2882418C/en active Active
- 2013-09-10 BR BR112015005168A patent/BR112015005168A2/pt not_active Application Discontinuation
- 2013-09-10 PE PE2015000315A patent/PE20150627A1/es active IP Right Grant
- 2013-09-10 NZ NZ630967A patent/NZ630967A/en unknown
- 2013-09-10 MX MX2015003079A patent/MX366913B/es active IP Right Grant
- 2013-09-10 RS RSP20190829 patent/RS59194B1/sr unknown
- 2013-09-10 PL PL13767176T patent/PL2892912T3/pl unknown
- 2013-09-10 PT PT13767176T patent/PT2892912T/pt unknown
- 2013-09-10 JP JP2015531318A patent/JP6243428B2/ja active Active
- 2013-09-10 SG SG11201501792RA patent/SG11201501792RA/en unknown
- 2013-09-10 EP EP13767176.4A patent/EP2892912B1/en active Active
- 2013-09-10 TW TW102132641A patent/TWI630212B/zh active
- 2013-09-10 ES ES13767176T patent/ES2731758T3/es active Active
- 2013-09-10 CN CN201380058427.0A patent/CN104955833B/zh active Active
- 2013-09-10 CR CR20150117A patent/CR20150117A/es unknown
- 2013-09-10 SI SI201331468T patent/SI2892912T1/sl unknown
- 2013-09-10 UY UY0001035023A patent/UY35023A/es not_active Application Discontinuation
- 2013-09-10 DK DK13767176.4T patent/DK2892912T3/da active
- 2013-09-10 ME MEP-2019-174A patent/ME03522B/me unknown
- 2013-09-10 AU AU2013312106A patent/AU2013312106B2/en active Active
- 2013-09-10 HU HUE13767176A patent/HUE044126T2/hu unknown
- 2013-09-10 WO PCT/US2013/059027 patent/WO2014040060A1/en active Application Filing
- 2013-10-09 UA UAA201503335A patent/UA115672C2/uk unknown
-
2015
- 2015-02-23 ZA ZA2015/01206A patent/ZA201501206B/en unknown
- 2015-03-05 CL CL2015000543A patent/CL2015000543A1/es unknown
- 2015-03-06 PH PH12015500491A patent/PH12015500491B1/en unknown
- 2015-03-09 IL IL237639A patent/IL237639B/en active IP Right Grant
- 2015-03-09 DO DO2015000054A patent/DOP2015000054A/es unknown
-
2016
- 2016-01-12 HK HK16100293.6A patent/HK1212355A1/xx unknown
-
2017
- 2017-02-15 US US15/433,100 patent/US10501489B2/en active Active
-
2019
- 2019-06-27 HR HRP20191165TT patent/HRP20191165T1/hr unknown
- 2019-07-02 CY CY20191100697T patent/CY1121776T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY35023A (es) | Derivados c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso | |
DOP2016000144A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
CO7210068A1 (es) | Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
SV2017005514A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
UY35467A (es) | Compuestos orgánicos | |
CR20160119A (es) | Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística | |
CU20140095A7 (es) | Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
NZ705213A (en) | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof | |
CU20140081A7 (es) | Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
UY36735A (es) | Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
ECSP15008851A (es) | Compuestos heteroaromáticos como inhibidores de btk | |
GT201400063A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
MX348862B (es) | Derivados c4-monometil triterpenoides y sus metodos de uso. | |
ECSP15045801A (es) | Inhibidores de la phd de 6(5hidroxi1hpirazol1il)nicotinamida | |
CU20140089A7 (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
ECSP14013215A (es) | Compuestos novedosos | |
UY32863A (es) | COMPUESTOS DE HEXAHIDROOXAZINOPTERINA PARA USO COMO INHIBIDORES DE mTOR | |
CO2019006687A2 (es) | Polimorfos | |
UY34356A (es) | Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
CL2018001210A1 (es) | Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico. | |
UY34773A (es) | Ácidos indanoiloxidihidrobenzofuranilacéticos como moduladores de la actividad de gpr40, composiciones que los contienen y sus usos | |
ECSP11011485A (es) | Espiro-epóxidos como productos intermedios. | |
UY35997A (es) | Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
UY34612A (es) | ?procedimiento para la preparación de derivados de isoxazolina azetidina quirales como agentes antiparasitarios?. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20210617 |